AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03814200
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single i.v. infusion of 100 mL saline 0.9% for 30 min
Trial: NCT01050764
Drug: Anti-thymocyte globulin, rabbit
RxNorm normalized name: anti-thymocyte globulin, rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
Trial: NCT01050764
Drug: CliniMACS CD34 Reagent System
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
Trial: NCT00409942
Drug: Torasemide Prolonged Release
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
Trial: NCT00409942
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
Trial: NCT02670785
Drug: Estradiol Vaginal Capsule (EVC)
RxNorm normalized name: estradiol Vaginal Cream
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
Trial: NCT03814200
Drug: ACT-246475
RxNorm normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
Trial: NCT00448227
Drug: famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally as a single individualized dose between 25-200 mg based on body weight.
Trial: NCT01201694
Drug: Surface-Controlled Water Soluble Curcumin
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 100 mg by mouth two times a day of a 28 day cycle.
Trial: NCT01201694
Drug: Surface-Controlled Water Soluble Curcumin MTD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose will be maximum tolerated dose (MTD) from Arm 1.
Trial: NCT00277030
Drug: Surfactant
RxNorm normalized name: Surfactant
DrugBank: Recombinant surfactant protein D (DB18438)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03814200
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
Trial: NCT04394130
Drug: ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
Trial: NCT00732745
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00732745
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00732745
Drug: vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04905667
Drug: GB221
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 mg/kg, single dose, intravenous infusion, 90-100 min
Trial: NCT04905667
Drug: Herceptin
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 mg/kg, single dose, intravenous infusion, 90-100 min
Trial: NCT00375076
Drug: enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00722839
Drug: agatolimod sodium
RxNorm normalized name: AGATOLIMOD SODIUM
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given subcutaneously
Trial: NCT03755739
Drug: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
Trial: NCT00280930
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00193492
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00193492
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00860925
Drug: active clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
Trial: NCT00830167
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Trial: NCT04440696
Drug: Lanthanum Polystyrene Sulphonate Powder
RxNorm normalized name: lanthanum carbonate Oral Powder
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
Trial: NCT04440696
Drug: Lanthanum Carbonate 500 MG
RxNorm normalized name: lanthanum carbonate 500 MG
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
Trial: NCT00860925
Drug: active ASA
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
Trial: NCT00860925
Drug: Clonidine Placebo
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
Trial: NCT00424970
Drug: acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01985724
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
Trial: NCT01985724
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Trial: NCT01985724
Drug: Granulocyte-colony stimulating growth factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
Trial: NCT03168035
Drug: NC-4016
RxNorm normalized name: 9-NC
DrugBank: Rubitecan (DB06159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
Trial: NCT01524016
Drug: 68Ga-DOTATATE
RxNorm normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
Trial: NCT01580046
Drug: iodixanol
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection
Trial: NCT01580046
Drug: iopromide
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
Trial: NCT00003350
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04070079
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TAF 25mg once daily orally, for 48 weeks
Trial: NCT00361387
Drug: d-methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral dosing for 8 weeks then cross over to placebo in random order
Trial: NCT01499160
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug is are to be taken orally. 2.5 mg once daily
Trial: NCT04510168
Drug: 11C-ER176
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)
Trial: NCT01499160
Drug: lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
Trial: NCT01499160
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug is to be taken orally. 5 mg once daily.
Trial: NCT02101476
Drug: Percocet
RxNorm normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/650mg
Trial: NCT04107727
Drug: Quizartinib
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.
Trial: NCT02361736
Drug: Hydroxyethyl Starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
Trial: NCT00564187
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A
Trial: NCT00564187
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
Trial: NCT01881737
Drug: Pregnenolone
RxNorm normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs.
Trial: NCT02474654
Drug: Bupivicaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg
Trial: NCT02474654
Drug: Epimorphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mcg
Trial: NCT01711567
Drug: tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tenofovir 300 mg qd
Trial: NCT01711567
Drug: entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: entecavir 0.5 mg qd
Trial: NCT01186562
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg PO daily
Trial: NCT04510168
Drug: Florbetaben
RxNorm normalized name: florbetaben
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi
Trial: NCT02725060
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
Trial: NCT02725060
Drug: isoproterenol
RxNorm normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
Trial: NCT04107727
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.
Trial: NCT00004216
Drug: cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004216
Drug: ceftriaxone sodium
RxNorm normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004216
Drug: ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004216
Drug: trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02566096
Drug: transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
Trial: NCT04107727
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
Trial: NCT03860948
Drug: Savolitinib Test Preparation
RxNorm normalized name: cranberry preparation
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (T): dry granulation savolitinib tablets.
Trial: NCT01007019
Drug: YH4808 100mg (repeat dose)
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 100mg (repeat dose)
Trial: NCT01007019
Drug: YH4808 200mg (repeat dose)
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 200mg (repeat dose)
Trial: NCT01007019
Drug: YH4808 400 mg (repeat doses)
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 400 mg (repeat doses)
Trial: NCT01007019
Drug: Esomeprazole 40mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 volunteers will be administered Esomeprazole 40mg
Trial: NCT03310619
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-PD-L1
Trial: NCT03310619
Drug: CC-122
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleiotropic Pathway Modifier
Trial: NCT03310619
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib
Trial: NCT03310619
Drug: CC-220
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-220
Trial: NCT03310619
Drug: Relatlimab
RxNorm normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Relatlimab
Trial: NCT03310619
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab
Trial: NCT03310619
Drug: CC-99282
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-99282
Trial: NCT01160640
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ceftrixone 250mg IM single dose
Trial: NCT01160640
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metronidazole 500 mg PO bid x 14 days
Trial: NCT03269955
Drug: Fibrinogen/thrombin-coated collagen patch
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
Trial: NCT03860948
Drug: Savolitinib Reference Preparation
RxNorm normalized name: cranberry preparation
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (R): wet granulation savolitinib tablets.
Trial: NCT02538484
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor
Trial: NCT03796429
Drug: GS+Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years).
Trial: NCT00002592
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00959621
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA 100 mg once daily per os
Trial: NCT01224457
Drug: Phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
Trial: NCT00959621
Drug: Klexane and ASA
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Klexane 40 mgx 1 sc and ASA 100 mg po
Trial: NCT00536198
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
Trial: NCT02922582
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00133679
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d